All In MedTech

Device Trial Radar · NCT03843320

Impact of SAVR and TAVR on Patient's Activity and Mobility

Impact of SAVR and TAVR on Patient's Activity and Mobility CAPABILITY Study

Last checked: Nov 20, 2026Latest source record: Dec 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

340

Planned (sponsor's estimate)

Start

Dec 2021

Primary completion

Dec 2023

Study completion Dec 2024

Sponsor

Lead sponsor
University of PadovaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Edwards Lifesciences; Ospedale San Bortolo di Vicenza; Azienda Ospedaliera di Padova
First posted
Feb 18, 2019

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 75 years, up to 89 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an independent, investigator-initiated, prospective multicenter observational study with restricted grant provided by Edwards Lifesciences that aims to describe baseline (preoperative) physical function and to assess and compare 6-month postoperative changes in the physical function of patients undergoing aortic stenosis (AS) treatment with either transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) implanted with Edwards valve type ("SAPIEN 3" and "SAPIEN XT" for TAVR; "INSPIRIS RESILIA", "EDWARDS INTUITY" and "Carpentier-Edwards PERIMOUNT Magna-Ease" for SAVR). Secondary objectives of this study are: to evaluate the validity of wearable devices in assessing physical function in such patients and subjects' compliance in wearing the device also after a very long follow-up time up to 12 months; to assess and compare 6-month postoperative changes in Health-Related Quality of Life (HRQoL), sleep quality, cognitive function of patients undergoing AS treatment with either TAVR or SAVR. Smart watch activity tracker "Vívoactive® HR" devices by "Garmin©" will be used in the study. Devices will be distributed to the patients at time of baseline assessment, along with a Bluetooth-paired smartphone provided with a prepaid data-only SIM-card and study-customised interface. Patients will be asked to wear the device 24 hours a day, 7 days a week, from the baseline assessment to the last follow-up, 12 months after baseline.

Conditions

  • Aortic Valve Stenosis

Interventions

  • SAPIEN 3Device

    Transcatheter aortic valve replacement

  • SAPIEN XTDevice

    Transcatheter aortic valve replacement

  • INSPIRIS RESILIADevice

    Surgical aortic valve replacement

  • EDWARDS INTUITYDevice

    Surgical aortic valve replacement

  • Carpentier-Edwards PERIMOUNT Magna-EaseDevice

    Surgical aortic valve replacement

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 6-minute walk test (6 MWT) at 1 monthTime frame: 1 month after treatment with TAVR/SAVR
  2. 6-minute walk test (6 MWT) at 3 monthsTime frame: 3 months after treatment with TAVR/SAVR
  3. 6-minute walk test (6 MWT) at 6 monthsTime frame: 6 months after treatment with TAVR/SAVR

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Azienda Ospedaliera di Padova

    Padova, PD, Italy

  • Azienda ULSS n.8 Berica, Vicenza - Ospedale San Bortolo

    Vicenza, VI, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.